Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tikun Olam

Explore full profile

Tikun Olam Ltd breeds proprietary cannabis strains and develops standardized products with accurate dosage

Tel Aviv-Yafo, IsraelFounded 2006Biotech & Life Sciences
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Tikun Olam and the history behind them.

About Tikun Olam

Tikun Olam, whose name translates from Hebrew as “to heal the world,” operates as a pioneer in the medical cannabis market. The company was established in 2005 by Tzahi Cohen in Tel Aviv, Israel, initially as a non-profit organization. It began by openly cultivating and distributing cannabis for free to patients, including many veteran soldiers, who were suffering from various ailments. This grassroots effort helped build momentum for cannabis liberalization in Israel.

In 2007, the company achieved a significant milestone by becoming the first to be granted a license by the Israeli Ministry of Health to grow and supply medical marijuana. This marked a pivotal moment, transitioning Tikun Olam into a limited company in 2010 following regulatory changes. The business model centers on the cultivation, research, development, and distribution of proprietary, genetically optimized cannabis strains designed for specific symptomatic relief. Revenue is generated through the sale of its medical cannabis products and by exporting its know-how and intellectual property to international partners in exchange for royalties and stakes in joint ventures. This strategy has led to a global presence with operations in the United States, Canada, Australia, and Europe.

Tikun Olam serves medical patients suffering from a wide range of conditions, including cancer, PTSD, Crohn's disease, colitis, epilepsy, and multiple sclerosis. The company's product line is extensive, including cannabis flower, pre-rolls, oils, tinctures, edibles, and topicals. A key achievement came in 2012 when Tikun Olam developed 'Avidekel,' a strain with high cannabidiol (CBD) content and minimal psychoactive THC, which garnered international media attention. This product allows patients to receive the therapeutic benefits of cannabis without the intoxicating effects. The company has built one of the world's largest patient treatment databases, which it uses to inform strain development and patient care, collaborating with physicians, hospitals, and researchers. This commitment to research includes numerous peer-reviewed studies and clinical trials, solidifying its reputation among medical practitioners.

Source: Dealroom company data

At a glance

Founded
2006
Headquarters
Tel Aviv-Yafo, Israel
Sector
Biotech & Life Sciences
Employees 1 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇮🇱 Israel · Tel Aviv-Yafo HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tikun Olam on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tikun Olam on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.